Licofelone in osteoarthritis: is this the awaited drug?  
a systematic review

Vinod Kumar P.*

Department of Pharmacology, Amala Institute of Medical Sciences, Thrissur, Kerala, India

Received: 09 March 2021  
Revised: 11 April 2021  
Accepted: 12 April 2021

*Correspondence:  
Dr. Vinod Kumar P.,  
Email: pvk1471@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Osteoarthritis is a progressive joint disease associated with aging in elderly is, characterized by pain, inflammation, and difficulty in movement. The pathways involved in the progression of this disease remain unclear. The mediators, eicosanoids and leukotrienes are produced by COX-1/COX-2 or 5-LOX. Physicians have always used nonsteroidal anti-inflammatory drugs to treat the pain associated with osteoarthritis. A competitive inhibitor of LOX-5 and COX-2 that has both analgesic and anti-inflammatory activity is licofelone; one of the most promising candidates for the treatment of osteoarthritis is under clinical trial in treatment. A significant reduction in cartilage volume was displayed. A significant improvement over baseline on the WOMAC index and GI tolerance was also observed. Improving the symptoms related pain sensation with a happier life. With new strategies in OA, new methods to target pain, inflammation and movement restrictions would be the ultimate goal in patient satisfaction for the future. Licofelone was found to be effective compared to NSAIDs or coxibs in the treatment of OA. Does this mean this could be the answer?

Keywords: Osteoarthritis, NSAIDs, COX/5-LOX dual inhibitors, Licofelone

INTRODUCTION

Osteoarthritis, an age-related joint disorder, is a progressive illness associated with joint pain, inflammation and inability to move the joints (Figure 1), is pro-inflammatory, and progresses with age.1,2 Lopez-Otin et al planned nine distinctive features of aging, supports the fact that chronic inflammation in aging and age-related conditions suggests inflammation to be a crucial link between aging and OA (Figure 2).3

The features in the progression of OA is still not clear and many factors like cytokines, prostaglandins (PGs), and leukotrienes (LTs), effect on the cartilage chondrocyte may be associated.4-5 PGs and LTs are known to cause joint damage, pain, or swelling if OA is severe, where the senescence-associated secretory phenotype (SASP) maybe a promoting factor.

Eicosanoids are arachidonate-derived lipid mediators, the prostanoids (PGs and thromboxanes) and LTs; generate the COX-1/COX-2 or 5-LOX enzymes. Leukotrienes are the most potent mediators of inflammation with their role in arthritic diseases, including osteoarthritis. Osteoblasts synthesize LTs. Higher levels of LTB4 and PGs have been reported in the joints of the patients with OA and LTB4 is thought to mediate the cartilage damage.5,7 Enzymes like cyclooxygenase (COX) and lipoxygenase (LOX), with cytochrome P450 (CYP) pathways, are associated with the arachidonic acid (ARA) pathway.8-11 The higher levels of leukotrineB4 (LTB4) and prostaglandins (PGs) have been reported in the joints of
the patients with OA wherein LTB4 is thought to mediate the cartilage damage.12,13 The role of eicosanoids in the pathophysiology of arthritic diseases, including osteoarthritis, was revealed in recent studies. In rheumatoid arthritis patients, elevated lipids in the synovial fluid seem to correlate with the phospholipids, PGE, and LTB4 with OA patients.14-16

High levels of serum or synovial fluid concentration of TNF-α, IL-1β, IL-6, IL-15, IL-17, IL-18, and NO in patients of OA were reported in studies. Prostacyclin (PGI2) and PGE2 play an important role by modulating the gastrointestinal mucosal defence and repair in the gastrointestinal tract.17,18 LOX/COX inhibitors block both the COX-1 and COX-2 pathways and the 5-LOX metabolic pathway by inhibiting the formation of PGI2 and PGE2, contributing to acute inflammation.19-21 NSAIDs inhibit the COX enzymes but have no anti-5-LOX activity to prevent the formation of leukotrienes (LTs). Physicians have always trusted the use of nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of OA. NSAIDs inhibit both COX-1 and COX-2, or coxibs (e.g., rofecoxib, celecoxib), that selectively inhibit COX-2, reduce the levels of PGs, resulting in relief from pain and inflammation is often associated with damage to gastric mucosa which is severe or with complications of the cardiovascular system, with a known fact that the use of NSAID is limited due to of gastrointestinal adverse effects compared to coxibs.10,12-14

The most promising dual inhibitor developed so far is licofelone which competitively inhibits COX-1/COX-2 and 5-LOX enzymes having analgesic, anti-inflammatory, antiplatelet effect and is currently under clinical evaluation for the treatment of OA.22,23 The combination of 5-LOX inhibitors or LT receptor antagonists with NSAIDs has reported benefits in not only relieving pain and inflammation but also preventing or reducing NSAID-induced gastric damage. This has lead to the concept of dual inhibition (i.e., COX and 5-LOX inhibition) emerging as an alternative and safe therapy for enhanced analgesic and anti-inflammatory effect with little or no gastric mucosal damage.24 An estimated cost of around 2% in developed countries is associated with osteoarthritis (OA) helping to reduce or stop its progression.25-28 Three COX/5-LOX dual inhibitors in the advanced stage of clinical development for OA are licofelone, flavocoxid and tepoxalin. Among these licofelone is a drug developed for humans, flavocoxid a medical food indicated for OA in humans and tepoxalin is approved for canines, each having a distinct mechanism of action that may affect safety and efficacy. Licofelone specifically inhibits the cyclooxygenase moieties of the COX enzymes as well as 5-LOX induction. The first dual inhibitor LOX-5 and COX-2, benoxaprofen, is no longer used due to liver toxicity another dual 5-LOX/COX inhibitor; flavocoxid is a USFDA-regulated prescription medical food for the clinical dietary management of the metabolic processes of OA also having antioxidant property.29,30 A promising candidate for the treatment of osteoarthritis is a competitive inhibitor of LOX-5 and COX-2 enzyme, licofelone, that has both analgesic and anti-inflammatory effects with initial studies indicating that licofelone (ML 3000); 2, 2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl-acetic acid was involved in phase III clinical trial displaying very good gastric safety, a positive effect on bone remodelling in osteoarthritis, reporting no adverse effects on the stomach. Licofelone has not yet been submitted for regulatory approval despite these promising results.31-33

**Literature search**

The keywords for identifying knee OA were licofelone osteoarthritis, OA in elderly, knee OA, (MeSH) or osteoarthritis, knee osteoarthritis, OA in elderly, COX-1, COX-2, lipoxigenase, 5-LOX, nonsteroidal anti-inflammatory drugs, naproxen, celecoxib, dual inhibitors (PubMed). The highest impact factor general and internal medicine journals, highest impact factor rheumatology journals, British medical journal, British journal of pharmacology, osteoarthritis cartilage, annual review of medicine, arthritis and rheumatism, annals of rheumatic diseases, nature clinical practice rheumatology, arthritis research and therapy, advanced therapeutics, seminars in arthritis and rheumatism; osteoarthritis cartilage, rheumatology (Oxford), drugs ageing, arthritis, clinical interventions in aging, current opinion in rheumatology; journal of rheumatology; lancet, current review musculoskeletal medicine, best practice and research in clinical rheumatology, P1000 research. Identifying journal articles with high methodological quality in journals with a high impact factor was searched.

**METHODS**

The elderly are associated with osteoarthritis, associated with the knees, hips, and other joints, giving the purpose of current investigation. The author independently searched words like osteoarthritis, osteoarthritis, OA in elderly, knee OA, cyclooxygenase, COX-1, COX-2, lipoxigenase, 5-LOX, nonsteroidal anti-inflammatory drugs, NSAID toxicity, naproxen, celecoxib, NSAID organ toxicity, arachidonic acid metabolism, osteoarthritis, and combinations across the databases and selected ten most relevant related articles to the over a period from 2002-2016, and summarized them.

Following international consensus regarding the core set of outcome measures for phase III clinical trials in OA, those participating in randomized control trials (RCTs) had to include at least self-reported pain and/or self-reported disability in the assessment.34 Pain in knee OA was measured by Western Ontario or McMaster universities osteoarthritis index (WOMAC pain subscale) or by a visual analog scale (VAS). The assessment for the patient-reported disability was done with WOMAC function subscale or by a short form 36 (SF-36).35-37
MRI and X-ray examinations were done at six months for MRI only for baseline and 12 and 24 months for X-ray. MRI was done to evaluate the changes in cartilage volume and X-ray examination to measure the mean and minimum joint space width (JSW) in the medial compartment. Questionnaires regarding symptoms were noted and the data for intention to treat (ITT) was presented and according to the protocol (ATP).38

<table>
<thead>
<tr>
<th>Drug</th>
<th>Phase</th>
<th>Patient cohort</th>
<th>Clinical endpoint</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Licofelone and naproxen</td>
<td>Phase III</td>
<td>In OA patients (n=148) for 12 weeks</td>
<td>30% improvement over baseline on the WOMAC index</td>
<td>An improvement over baseline on the WOMAC index</td>
<td>31-33</td>
</tr>
<tr>
<td>Licofelone and naproxen</td>
<td>-</td>
<td>52 week, double-blind study (n=710) patients with OA of the knee.</td>
<td>General and GI tolerability</td>
<td>Licofelone had a lower incidence of hypertension aggravation than naproxen.</td>
<td>34, 54, 55</td>
</tr>
<tr>
<td>Licofelone and celecoxib</td>
<td>-</td>
<td>Patients (n=148) with OA 12-week clinical study</td>
<td>Symptomatic osteoarthritis of the knee</td>
<td>Licofelone was as effective as celecoxib, showed better tolerability with a lower incidence of adverse events.</td>
<td>31-33</td>
</tr>
<tr>
<td>Licofelone</td>
<td>RCT</td>
<td>Knee OA (355 patients)</td>
<td>Cartilage volume and JSN assessed by quantitative MRI</td>
<td>Significant reduction in cartilage volume, JSN unchanged</td>
<td>34, 58, 59</td>
</tr>
</tbody>
</table>

JSN: joint space narrowing, WOMAC: Western Ontario and McMaster universities arthritis index, RCT: randomized controlled trial

**Inclusion criteria**

Inclusion criteria for current review were; matching of at least one keyword, articles that included primary knee OA as an intervention group assessed clinically or radiological method, with or without meta-analysis of randomized controlled trials, phase 3 results, scientific journal search, articles displaying relief from symptoms and wellbeing of patients with knee related pain, a detailed description of the non-pharmacological and non-surgical intervention and their full version, in English.

**Exclusion criteria**

Inclusion criteria for current review were; papers with an experimental or control group composed of any animals, papers with participants that do not have a knee OA (healthy volunteers) or who have secondary knee OA (traumatic or post-surgical), papers with exclusively pharmacological or surgical interventions, any article in trials, any case reports, any books and papers presented at conferences, papers with subjects with other diseases, namely cancer, heart diseases, kidney diseases, neurological diseases, respiratory diseases, rheumatoid arthritis, gout arthritis, septic arthritis, or Paget's disease and papers included exclusively only with osteoarthritis in the hip, foot, shoulder, elbow, wrist, and/or fingers.

**RESULTS**

Total 148 patients who received either licofelone (200 mg bid) or naproxen (500 mg bid) for 12 weeks with OA, with the WOMAC index displaying a 30% improvement over baseline readings, the two groups responded with 69% in the licofelone group (N=72) and 68% in the naproxen group (N=76).39-54 GI side effects of 14% and gastroduodenal ulcers developed in 1.5% with licofelone treated patients whom compared to 26% and 15% with naproxen was reported.55 In another study involving 148 patients the improvement in the mean WOMAC index with licofelone was 23.3 mm and with naproxen 21.5 mm. 13.9% (licofelone) and 26.3% (naproxen) patients reported GI adverse events. The WOMAC index of 69.4% with licofelone treated patients and 68.4% with naproxen was reported.55 In 710 patients with OA knee for 52 weeks, assessing the long-term safety and efficacy of licofelone in a dose of 100 or 200 mg bid was compared with naproxen 500 mg bid, licofelone showed similar efficacy to naproxen at fourth week in both doses and licofelone showing a better, general and GI tolerability than naproxen. GI ulcers, for 100 mg bid dose of licofelone showed 0.14%, and for 200 mg bid dose 0.39% and naproxen 2.5% in phase III studies.59-55

In a 52 week, multicentre, double-blind, phase III trial, tolerability and efficacy of licofelone compared with naproxen, the efficacy of licofelone 200 mg was found to be similar to naproxen, showing superior tolerability of licofelone compared with naproxen. WOMAC pain score rates after 12 weeks of therapy displayed 77.9 and 76.4% in licofelone and naproxen respectively, that showed a more than >30% improvement in score from baseline.56-58

A study that included 355 patients with knee OA that were studied to prove superiority of MRI over X-ray in a multicentre clinical trial, to explore the effects of licofelone as a disease modifying osteoarthritis drug in comparison with naproxen in patients with knee OA, using MRI and X-ray, receiving either licofelone 200 mg...
twice daily or naproxen 500 mg twice daily. After 12 and 24 months, licofelone markedly reduced the cartilage loss for intention to treat (ITT), while in joint space width (JSW), licofelone showed less reduction than naproxen, but did not reach significant levels. OA symptoms reduced equally with licofelone and naproxen, and licofelone significantly reduced cartilage volume over time, providing a protective effect in patients with knee OA.37-59

The role played by eicosanoids in the pathophysiology of arthritic diseases, including osteoarthritis, has been revealed and the role of leukotriene-B4 (LTB4) synthesis and IL-1β by synovium in osteoarthritis. Cheng et al, 2004, suggested the PG-affected processes in OA are affected by other mediators like LTx. LTB 4 in osteoblasts stimulates and enhances the production of IL-1C and tumour necrosis factor-β (TNFβ). The synthesis of LTB4 and IL-1β was significantly increased by NSAIDs explaining how some NSAIDs accelerate the progression of clinical osteoarthritis.44-49-52

148 patients who received either licofelone (200 mg bid) or naproxen (500 mg bid) for 12 weeks with OA, with the WOMAC index displaying a 30% improvement over baseline readings. Similar efficacy was observed in the two groups, with 69% responding in the licofelone group (N=72) and 68% in the naproxen group (N=76). Licofelone treated patients reported GI side effects of 14%, in whom gastroduodenal ulcers developed in 1.5%, compared with 26% and naproxen reported 15%. Abdominal pain or discomfort was reported as the most common adverse effect with 4.2% of patients on licofelone compared to 7.9% on naproxen.55

A double-blind study in 710 patients with OA knee for 52 weeks assessing the long-term safety and efficacy of licofelone (100 or 200 mg bid) was compared with naproxen (500 mg bid) of licofelone showed similar efficacy to naproxen at 4th week in both doses. The efficacy of licofelone improved throughout the 52 weeks study. Licofelone showed better general and GI tolerability than naproxen. In phase III studies for GI ulcers, for 100 mg bid dose of licofelone was 0.14%, for 200 mg bid dose 0.39% and naproxen 2.5%.29, 53-55

In a study involving 148 patients with knee OA for 12 weeks who were treated with licofelone 200 mg bid or naproxen 500 mg bid, the efficacy was evaluated using the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index, with a 30% improvement compared to baseline in responders, the mean WOMAC index with licofelone improvement was 23.3 mm and with naproxen 21.5 mm. 69.4% with licofelone treated patients an improvement compared to baseline in responders, the WOMAC index displaying a 30% improvement over baseline readings. Similar efficacy was observed in the two groups, with 69% responding in the licofelone group (N=72) and 68% in the naproxen group (N=76). Licofelone treated patients reported GI side effects of 14%, in whom gastroduodenal ulcers developed in 1.5%, compared with 26% and naproxen reported 15%. Abdominal pain or discomfort was reported as the most common adverse effect with 4.2% of patients on licofelone compared to 7.9% on naproxen.55

In a study involving 148 patients with knee OA for 12 weeks who were treated with licofelone 200 mg bid or naproxen 500 mg bid, the efficacy was evaluated using the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index, with a 30% improvement compared to baseline in responders, the mean WOMAC index with licofelone improvement was 23.3 mm and with naproxen 21.5 mm. 69.4% with licofelone treated patients and 68.4% with naproxen was the WOMAC index. 13.9% (licofelone) and 26.3% (naproxen) patients reported GI adverse events.55

In a 52-week, multicentre, double-blind, phase III trial, tolerability and efficacy of licofelone compared with naproxen, demonstrated that licofelone was effective as naproxen in osteoarthritis.56-57 Symptomatic knee OA, was defined as per guidelines of American college of rheumatology, in patients who had discontinued NSAID therapy 3-14 days before the first visit, were randomized to receive licofelone in a dose of either 100 mg bid, 200 mg bid, or naproxen 500 mg bid. The efficacy of licofelone 200 mg was found to be similar to naproxen with results showing superior tolerability of licofelone compared with naproxen.58

DISCUSSION

Only clinical studies in phase 3, randomized control trial (RCT) with their results were looked and preclinical studies were ignored. The prevalence of arthritis with OA is high and is the most common disorder in the population. 1.3 to 1.75 million people is affected with OA in England and Wales, while every year, around 6 million new cases are diagnosed in France. This number is increasing year after year, especially in the elderly mainly associated with musculoskeletal disorders of physical and functional impairments, comprising medical intervention costs, premature mortality, and short-term disability, leaving an impact on the quality of life.39-41 Details of study related to licofelone is very limited and reports are found only in a few reviews and press releases.42-43

Figure 1: Pain pathway and OA.

Figure 2: Progression of OA.
The efficacy and tolerability of licofelone compared with selective COX-2 inhibitor celecoxib in patients with OA in a multicentre, randomized, double-blind, parallel-group, phase III trial conducted over 12 weeks. Results indicated that treatment with licofelone 200 mg twice daily was as effective as celecoxib 200 mg once daily, with similarity in GI adverse effects in both groups, with licofelone reporting fewer incidences of peripheral edema than celecoxib.

The inhibition of COX alone the inhibition of both 5-LOX and COX (i.e., COX-1 and COX-2) might counteract inflammatory vascular changes and leukocyte induction, resulting in more anti-inflammatory action and a better safety profile of the gastrointestinal tract compared to COX alone and a new anti-inflammatory drug could cover all the therapeutic needs in elderly patients that is the need of the hour having no genotoxic effects. LOX/COX inhibitors seem to positively affect cartilage metabolism, slowing the degenerative process of OA, reducing pain and pain-related disability. Results indicate the efficacy of licofelone therapy was as effective as naproxen. WOMAC pain score rates of 77.9 and 76.4% in the licofelone and naproxen respectively after 12 weeks of therapy, showed >30% improvement in score from baseline was observed.

Gracia in 2004 revealed licofelone treatment was associated with a dose-dependent improvement in WOMAC pain scores from baseline and the efficacy of licofelone 200 mg was similar to that of naproxen with 26, 39, and 52 weeks showing greater efficacy. Licofelone showed superior tolerability regarding GI adverse events, cardiovascular adverse events compared with naproxen, with lifelong treatment groups experiencing fewer adverse events than naproxen group with 100 and 200 mg. No clinically relevant variations in laboratory parameters or vital were found in the long-term licofelone therapy. Clinical data suggests licofelone was as effective as conventional NSAIDs or coxibs in improving the symptoms of OA, with the advantage of improved GI tolerability and with few or no incidence of peripheral edema, suggesting an alternative for OA patients for long term treatment.

A study that included 355 patients with knee OA were studied to explore the effects of licofelone as a disease-modifying osteoarthritis drug in comparison with naproxen in patients with knee OA, using MRI and X-ray examination in a randomized manner receiving either licofelone 200 mg twice daily or naproxen 500 mg twice daily in 2009. MRI and X-ray examinations were done at six months for MRI only for baseline and 12 and 24 months for X-ray. MRI was done to evaluate the changes in cartilage volume and X-ray examination to measure the mean and minimum joint space width (JSW) in the medial compartment. Questionnaires regarding symptoms were noted, intention to treat (ITT) data was presented. At 12 and 24 months, licofelone markedly reduced the cartilage loss for ITT. In JSW, licofelone showed less reduction than naproxen, significance levels were not reached. OA symptoms reduced equally with licofelone and naproxen, but licofelone significantly reduced cartilage volume over time, providing a protective effect in patients with knee OA proving the superiority of MRI over X-ray in a multicentre clinical trial and for cell senescence, cell proliferation is not a requirement, that occurs after repetitive stress to tissues and cells. This may explain chondrocyte senescence detected in OA tissue where chronic repetitive loading is experienced and excessive loading associated with the development of OA and the meniscus, being a source of inflammatory mediator in the joint. Brophy et al reported that the pro-inflammatory cytokine IL-1β and the matrix-degrading enzymes were highly expressed in meniscal tissue isolated from young subjects (<40 years old) than from older subjects (>40). Further studies are needed to better understand its role in OA, leading to new interventions, targeting inflammation, and reducing pain and disability in older adults with OA and joint tissue destruction. Freund et al reported various inducers of cell senescence like senescence-associated secretory phenotype (SASP) that could be a promoting factor in age related pathologies like osteoarthritis, with increased levels of inflammatory mediators, and the mechanism includes DNA damage and activation of the p38 MAP kinase suggesting, patients who receive long-term treatment of NSAID, may be associated with an increased rate of OA progression.

**Current perspectives**

Clinical studies have demonstrated that licofelone; effectively treat OA and results are comparable to the conventional NSAIDs, naproxen, and diclofenac. It is well-tolerated with fewer side effects, suggesting that dual inhibition of COX and 5-LOX may reduce the undesirable GI side effects associated with NSAIDs. The new class of the LOX/COX inhibitors presents several beneficial and promising therapeutic effects that could be very important in the elderly. Based on pharmacological studies, it has been suggested that licofelone may be a disease-modifying drug. Licofelone could be a better alternative to NSAIDs and selective COX-2 inhibitors in treatment of OA, but future clinical studies are required to study the effects of the renal side effects of licofelone. Although it has been suggested that the rate of adverse events associated with licofelone may be comparable to selective COX-2 inhibitors with the possibility of less risk of cardiovascular and thromboembolic complications, there is no direct clinical evidence to support this, and further trials are needed. Whether these data are the reason why licofelone not progressed since its positive Phase III data is unclear.

**CONCLUSION**

Licofelone, a new class of anti-inflammatory agents is the need of the hour for the elderly, as traditional and more recent ones have failed in safety profile. Licofelone,
would an ideal disease modifying drug with better tolerability and acceptability for its role in OA with a mechanism of action that may be associated with the inhibition of LTB4, that is responsible for damage of the structural changes of joints. The long-term improvement in a patient in combination with advanced disease modifying treatments for osteoarthritis (DMOADs), might lead to the development of personalized OA therapeutics. Larger clinical trials need to be done as there is inadequate of published data, especially in the elderly, which seems to be the main drawback/limitation. Licofelone is shown to be as effective as conventional NSAIDs or coxibs in the recovery of symptoms related OA, so does this mean, it could be the answer for osteoarthritis therapy that are still unmet?

Recommendations

The main drawback of licofelone is lack of published data, regarding their clinical effectiveness and safety of COX/LOX dual inhibitors. Licofelone, is a competitive inhibitor of cyclooxygenase1 and 2 (COX 1 and 2) and 5-lipoxygenase (5-LOX), that possess both analgesic and anti-inflammatory properties with a positive effect on bone remodelling in osteoarthritis. Like conventional NSAIDs, the COX and 5-LOX dual inhibitors decrease the production of PGs with fewer general and GI side effects compared to NSAIDs. This could be an ideal disease modifying drug for arresting the pathophysiology of OA that enables better tolerability and acceptability.

ACKNOWLEDGEMENTS

Author is thankful to his guide, co-guide, colleagues and staff of the research centre for their contribution in current investigation.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

20. Rotondo S, Krauze-Brzóska K, Manarini S, Evangelista V, Cerletti C, Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically


Cite this article as: Vinod KP. Licofelone in osteoarthritis: is this the awaited drug? A systematic review. Int J Basic Clin Pharmacol 2021;10:564-71.